S. Agoussi

Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial

N. Halama, D. Jäger, A. Eggermont, 2018, Oncoimmunology.

Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma

N. Sonenberg, A. Eggermont, J. Adam, 2018, Nature Medicine.

Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization.

A. Eggermont, J. Adam, C. Robert, 2016, Cancer research.

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies

A. Eggermont, C. Robert, N. Ribeiro, 2014, Nature.

Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma

N. Sonenberg, A. Eggermont, J. Adam, 2018, Nature Medicine.